Given the beneficial effects of GLP-1 on glucose metabolism, its weight-loss potential, and the cardioprotective properties, there was an immense interest in developing pharmacological compounds that could mimic the action of GLP-1 and be resistant to the degradation of DPP-4 in order to be used in T2DM management. This evidence concerns the gene GCG and type 2 diabetes mellitus.